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Abstract
Background: The hemagglutinin (HA) of influenza viruses is a possible target for antiviral drugs because of its key
roles in the initiation of infection. Although it was found that a natural compound, Stachyflin, inhibited the growth
of H1 and H2 but not H3 influenza viruses in MDCK cells, inhibitory activity of the compound has not been
assessed against H4-H16 influenza viruses and the precise mechanism of inhibition has not been clarified.
Methods: Inhibitory activity of Stachyflin against H4-H16 influenza viruses, as well as H1-H3 viruses was
examined in MDCK cells. To identify factors responsible for the susceptibility of the viruses to this compound,
Stachyflin-resistant viruses were selected in MDCK cells and used for computer docking simulation.
Results: It was found that in addition to antiviral activity of Stachyflin against influenza viruses of H1 and H2
subtypes, it inhibited replication of viruses of H5 and H6 subtypes, as well as A(H1N1)pdm09 virus in MDCK cells.
Stachyflin also inhibited the virus growth in the lungs of mice infected with A/WSN/1933 (H1N1) and A/chicken/
Ibaraki/1/2005 (H5N2). Substitution of amino acid residues was found on the HA2 subunit of Stachyflin-resistant
viruses. Docking simulation indicated that D37, K51, T107, and K121 are responsible for construction of the
cavity for the binding of the compound. In addition, 3-dimensional structure of the cavity of the HA of
Stachyflin-susceptible virus strains was different from that of insusceptible virus strains.
Conclusion: Antiviral activity of Stachyflin was found against A(H1N1)pdm09, H5, and H6 viruses, and identified a
potential binding pocket for Stachyflin on the HA. The present results should provide us with useful information for
the development of HA inhibitors with more effective and broader spectrum.
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Background
Influenza A virus is widely distributed in birds and mam-
mals, including humans, and causes seasonal and pandemic
influenza. For the prevention and therapy of influenza,
anti-influenza drugs play an important role in addition to
vaccination. Currently available anti-influenza virus drugs
are M2 inhibitors (Amantadine and Rimantadine) and
neuraminidase (NA) inhibitors (Oseltamivir, Zanamivir,
Peramivir, and Laninamivir) [1,2]. The M2 transfers protons
into the infecting virus in the endosome at low pH, and the
M1 is dissociated from the genome-transcriptase complex
[3]. M2 inhibitors block ion channel activity and inhibit the
influx of protons, thereby exhibiting antiviral activity
against influenza A viruses [1]. At the end of the virus life
cycle, the NA catalyses the cleavage of terminal sialic acid
from glycoconjugates on the host cell surface to release
progeny virions [4]. Of these anti-influenza virus drugs, the
NA inhibitors, which interfere with the release of the virus,
are used clinically since they are broadly effective [5]; how-
ever, concern has been raised because of the isolation of
NA inhibitor-resistant viruses from clinical samples [6].
Therefore, it is expected to develop drugs targeting other
virus proteins than the NA and M2.
Hemagglutinin (HA) is a surface glycoprotein of influ-
enza A virus, and is a possible target of antiviral drugs
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because of its key roles in the initiation of infection.
Each monomer of the trimeric HA is composed of 2
subunits, HA1 and HA2. The HA1 has a receptor bind-
ing domain, and the HA2 mediates the fusion of the
virus envelope with the cellular membrane [7]. Several
studies have identified compounds which inhibit viral
infection by blocking the binding of the HA to sialic acid
receptor on the host cell surface (cyanovirin-N and
trisphenol-sialyllactose) or fusion step (TBHQ, BMY-
27709, CL-385319, and N-carboxamide) [8-12]; however,
for many of these inhibitors, the antiviral spectrum is
limited to the HA of certain subtypes, so that they have
not been used clinically. To develop more effective HA
inhibitors, further investigations of these HA inhibitors
and the analysis of the attachment and fusion steps of
influenza virus infection in the host cells are needed.
It was found that a sesquiterpene derivative, Stachyflin,
inhibited replication of H1 and H2 influenza A viruses
in vitro [13,14] and in vivo [15,16]. Although Stachyflin
is postulated to inhibit the fusion step, its precise mech-
anism has not been clarified. In the present study, it is
revealed that Stachyflin inhibit the growth of H1, H2,
H5, and H6 influenza viruses by binding the site of the
HA2 and preventing the HA from fusion of the virus en-
velope with cellular membrane.
Results
Antiviral activity of stachyflin in vitro and in vivo
The antiviral spectrum of Stachyflin was determined by
measuring its inhibitory effect on the replication of 31
influenza virus strains of H1-H16 subtypes in Madin-
Darby canine kidney (MDCK) cells. The antiviral effects
were evaluated in various concentrations of Stachyflin
up to 6.50 μM by virus-induced cytopathic effects (CPE).
Stachyflin inhibited the replication of H1 including A
(H1N1)pdm09 virus, H2, H5, and H6 subtype influenza
virus strains, but not that of the other subtype strains.
Susceptibility of the viruses to Stachyflin varied with the
strains (Table 1). In all of the viruses tested, AWSN/
1933 (H1N1) (WSN) showed the highest susceptibility
to Stachyflin.
The antiviral activity of Stachyflin in mice challenged
with A/Kumamoto/5/1967 (H2N2) was evaluated in pre-
vious study [15,16]. To confirm whether the antiviral ac-
tivity in vitro can be applied to in vivo, the virus titers in
the lungs of mice infected with WSN or A/chicken/
Ibaraki/1/2005 (H5N2) (Ibaraki) 72 h post-inoculation
were evaluated. WSN showed efficient replication and
was lethal to mice, while infection with Ibaraki, a low
pathogenic H5 avian influenza virus, was not lethal. Al-
though mice treated with Stachyflin did not reduce the
weight loss induced by virus challenge, only both groups
of mice treated with Stachyflin at 100 mg/kg/day showed
significantly lower mean virus titers in the lungs than
each control group (Figure 1). In mice infected with
WSN, the mean virus titer in the lungs of mice treated
with Stachyflin at 100 mg/kg/day was 103.5 50% tissue
culture infectious dose per gram (TCID50/g) whereas
that of control mice was 106.2 TCID50/g. In mice
infected with Ibaraki, the mean virus titer in the lungs of
mice treated with Stachyflin at 100 mg/kg/day was 103.4
TCID50/g, whereas that of control mice was 10
5.4
TCID50/g. Thus, Stachyflin showed inhibitory activity on
virus growth in vitro and in vivo. In these experiments,
CPE induced by Stachyflin was not observed even in the
Table 1 Antiviral activity of Stachyflin on influenza
A virus
Subtype Virus strain EC50 (μM)
a
H1 A/WSN/1933 (H1N1) 0.05
A/swine/Hokkaido/2/1981 (H1N1) 0.24
A/Puerto Rico/8/1934 (H1N1) 0.49
A/Narita/1/2009 (H1N1) pdm 1.95
H2 A/Singapore/1/1957 (H2N2) 0.16
H3 A/duck/Hokkaido/5/1977 (H3N2) >6.50
H4 A/duck/Czech/1956 (H4N6) >6.50
H5 A/Hong Kong/483/1997 (H5N1) 1.95




A/whooper swan/Mongolia/3/2005 (H5N1) 4.70
A/peregrine falcon/Hong Kong/810/2009 (H5N1) >6.50





H7 A/turkey/Italy/4580/1999 (H7N1) >6.50
A/chicken/Netherland/2586/2003 (H7N7) >6.50
H8 A/turkey/Ontario/6118/1968 (H8N4) >6.50
H9 A/chicken/Yokohama/aq-55/2001 (H9N2) >6.50
A/Hong Kong/1073/1999 (H9N2) >6.50
H10 A/chicken/Germany/N/1949 (H10N7) >6.50
H11 A/duck/England/1/1956 (H11N6) >6.50
H12 A/duck/Alberta/60/1976 (H12N5) >6.50
H13 A/duck/Siberia/272PF/1998 (H13N6) >6.50
H14 A/mallard/Astrakhan/263/1982 (H14N5) >6.50
H15 A/duck/Australia/341/1983 (H15N8) >6.50
H16 A/black-headed gull/Sweden/5PF/1999 (H16N3) >6.50
a The compound concentration producing 50% inhibition of virus replication,
as estimated by microscopic scoring of the CPE. The data shown are the
means of 3 experiments.
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highest concentration, 6.50 μM in MDCK cells and
weight changes of mice were not observed even in ad-
ministration of 100 mg/kg/day for 3 days.
Selection of stachyflin-resistant virus clones
To determine the amino acids which contribute to the sus-
ceptibility of the viruses to Stachyflin, Stachyflin-resistant
virus clones were selected from WSN, A/Puerto Rico/8/
1934 (H1N1) (PR8), Ibaraki, and A/duck/Taiwan/4801/
1990 (H6N5) (Taiwan). Six Stachyflin-resistant virus clones
were selected from WSN (WSN R1-R6) and 2 clones from
PR8 (PR8 R1-R2) by single passage in MDCK cells in the
presence of 0.52 or 1.30 μM of Stachyflin. The frequency of
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Figure 1 Antiviral activity of Stachyflin in mice. Four BALB/c mice were intranasally infected with 10 MID50 of WSN (A) or Ibaraki (B). After
inoculation, the solution of Stachyflin in polyethylene glycol 400 was intraperitoneally administered to each group every 12 h for 72 h. At 72 h
post-inoculation, mice were sacrificed and the lungs were collected for virus titration. Dashed lines indicate virus titer less than the detectable
dose (101.5 TCID50/g). *, P<0.05 compared to results for controls. **, P<0.01 compared to results for controls.
Table 2 The amino acid substitutions in the HA2 and character of Stachyflin-resistant (R) virus clones
Virus EC50 (μM) Amino acid position in HA2
a ⊿pHc
37 51 85 91 98 107 110
WSN Wild type 0.02 D K D I L T F 0.0
R1 >6.50 N -b - - - - - 0.3
R2 >6.50 - R - - - - - −0.3
R3 >6.50 - - H - - - - 0.0
R4 >6.50 - - - - - I - 0.2
R5 >6.50 - - - - V - - −0.2
R6 >6.50 - - - F - - - 0.0
PR8 Wild type 0.49 D K D I L T F N.D.d
R1 >6.50 - - - - S - - N.D.
R2 >6.50 - - - - - - S N.D
Ibaraki Wild type 0.17 D K D I L T F N.D
R1 >6.50 - R - - - - - N.D.
Taiwan Wild type 0.44 D K D I L T F N.D.
R1 >6.50 - R - - - - - N.D.
a H3 subtype numbering.
b Dash (-) means the same amino acid as the wild type virus.
c The pH at which 50% hemolysis of the wild type virus is 6.0. The values indicate the difference of the pH at which 50% hemolysis between the
Stachyflin-resistant virus clones and wild type virus.
d Not determined.
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Meanwhile from Ibaraki and Taiwan, Stachyflin-resistant
virus clones (Ibaraki R1 and Taiwan R1) were selected by 3
passages in the presence of 1.30 μM of Stachyflin. The clones
were plaque-purified and propagated in MDCK cells in the
presence of Stachyflin. The replication of these Stachyflin-
resistant virus clones was not inhibited even with 6.50 μM
Stachyflin (Table 2).
Nucleotide sequences of the HA genes of the wild type
and Stachyflin-resistant virus clones were determined. All
of the mutants had a single amino acid substitution in the
HA2 (Table 2). The number of amino acid residue of HA2
starts from GLF motif and is common in these strains. Of
these amino acid substitutions, K51R was common in the
HAs of Stachyflin-resistant virus clones of WSN, Ibaraki,
and Taiwan. These amino acid substitutions were mapped
on the structure of the HA monomer (Figure 2). Although
each of the amino acid substitutions was observed in the
stem region of the HA2, it was impossible to form a bind-
ing site for Stachyflin by the distance. To confirm that each
single mutation was responsible for Stachyflin resistance,
rgWSN mutants, which have one amino acid substitution
of the mutants, were generated by reverse genetics and
site-directed mutagenesis and were characterized. The rep-
lication of rgWSN mutants was not inhibited by 6.50 μM
Stachyflin, indicating that all the amino acid substitutions
were responsible for Stachyflin resistance (Table 3).
Optimal pH for hemolysis of stachyflin-resistant virus
clones
Influenza virus mediates the hemolysis of chicken red
blood cells (cRBC), which has been thought to represent
the fusion of the virus envelope with cellular membrane
[17]. Using a hemolysis assay, the effect of Stachyflin on
the fusion of WSN wild type and Stachyflin-resistant virus
clones was assessed. Stachyflin inhibited the hemolysis of
cRBC induced by the wild type virus but not that by the
mutants. In addition, optimal pH for fusion, at which 50%
hemolysis occurred, shifted from 6.0 for the wild type
virus to as follows: WSN R1: 6.3, R2: 5.7, R4: 6.2, and R5:
5.8 (Table 2).
Figure 2 Schematic representation of the positions of amino acid
substitutions involved in Stachyflin resistance. Three-dimensional
image of the H1 HA molecule was created with data from X-ray
crystallography of PR8 (PDB code: 1RU7) in the Protein Data Bank
Japan and Discovery Studio Visualizer 1.6. Yellow spheres on the HA
molecule indicate the positions of amino acid substitutions in
Stachyflin-resistant virus clones of WSN selected in the presence of
Stachyflin, and red sphere indicates that of PR8. Orange sphere
indicates the position of amino acid substitution observed in both
Stachyflin-resistant virus clones of WSN and that of PR8. The positions
of amino acids correspond to the H3 HA numbering.
Table 3 Character of rgWSN and rgStachyflin-resistant
virus clones
Virus EC50 (μM) Amino acid position in HA2
a
37 51 85 107
rgWSN Wild type 0.02 D K D T
rgR1 >6.50 N -b - -
rgR2 >6.50 - R - -
rgR3 >6.50 - - H -
rgR4 >6.50 - - - I
a H3 subtype numbering.
b Dash (-) means the same amino acid as the wild type virus.
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Relationship of amino acid substitution and the structure
of potential binding pocket for stachyflin in the HA
To predict the possible docking model for Stachyflin in
the HA trimer of WSN, PR8, Ibaraki, and Taiwan, com-
puter docking simulations of Stachyflin with these HAs
were performed. On the surface of these HA trimers, first,
the binding pocket for Stachyflin was supposed to be lo-
cated in a large cavity on the HA2 region, because most
amino acid substitutions found on the HA of Stachyflin-
resistant virus clones were in this cavity. In the cavity, we
found a potential binding pocket for Stachyflin, which was
formed by helix A and helix D of the HA2 subunit
(Figure 3A, B). This binding pocket contained the resi-
dues, D37, K51, and T107, which were substituted in the
HAs of Stachyflin-resistant virus clones (Figure 3B). In
addition, a residue identified as a Stachyflin-resistant
mutation previously [14], K121, was also contained in the
region of the binding pocket (Figure 3B). It was also found
that K51 and T107 made a hydrogen bond between helix
A and helix D, which may stabilize the structure of the
binding pocket.
Using computer docking modeling, it was investigated
that how Stachyflin makes bonds with the amino acid
around the binding pocket. In the present study, 2 possible
docking models of Stachyflin and the HA were proposed
(Figure 3B). In one model represented by orange-colored
Stachyflin, Stachyflin bound to the site in the vicinity of
T107 in the binding pocket, which is similar to that in a
previous report [18] (Figure 3B). In the other model repre-
sented by yellow-colored Stachyflin, Stachyflin bound dir-
ectly to D37 and K121 (Figure 3B). Both models were
different from that in a previous study which postulated
that Stachyflin forms a hydrogen bond with both K51
(helix A) and K121 (helix D) [14].
Discussion
Anti-influenza virus drugs are important for the preven-
tion and treatment of seasonal and pandemic influenza.
The HA inhibitor is a candidate drug which inhibits
virus attachment to or penetration into the host cells.
Most fusion inhibitors hitherto reported had H1 and H2












Figure 3 The predicted docking model of Stachyflin with the H5 HA of Ibaraki. Three-dimensional image of the HA trimer of Ibaraki was
created based on the data from X-ray crystallography of A/Vietnam/1194/2004 (H5N1) (PDB code: 2IBX), and the sequence data of Ibaraki by
homology modeling. (A) Residues colored in green indicate the region of the binding pocket for Stachyflin. The binding pocket is predicted to
exist between helix A and helix D of the HA2 subunit and be surrounded by hydrogen bonds of D37-K121 and K51-T107, D37 to K51, and T107
to K121 residues in the HA2. (B) Binding position of Stachyflin in the binding pocket of the HA was predicted by docking simulation in Molegro
Virtual Docker. The structure of Stachyflin is colored in yellow or orange and the residues constructing the binding pocket are in green. Two
possible docking poses of Stachyflin with the HA were obtained, which are indicated as the positions of orange-colored Stachyflin (above) and
yellow-colored Stachyflin (below) in the HA model. In the binding pocket, D37 may make a water-intermediate hydrogen bond with K121, and
K51 may make a hydrogen bond with T107. (C) Dashed line indicates the salt bridge between D85 and K83 of another HA2 subunit. The distance
between these residues was 2.55 Å.
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been examined their activities against H4-H16 viruses
[10,11,19], except for CL-385319 [20]. Stachyflin was
also reported as H1 and H2 subtype-specific fusion in-
hibitor and its 50% inhibitory concentration (IC50) was
0.2-0.6 μM [13]. The results of the present study re-
vealed that Stachyflin had subtype-specific antiviral
activities against not only H1 and H2 viruses, but also
H5, including highly pathogenic avian influenza viruses,
and H6 viruses, as well as A(H1N1)pdm09 virus in MDCK
cells and its IC50 was 0.05-4.7 μM (Table 1). It is revealed
that cytotoxicity of Stachyflin to the MDCK monolayers
did not appear up to a concentration of 75 μM [13], how-
ever, for its insolubility [16], antiviral activity in vitro was
assessed up to a concentration of 6.5 μM. In the present
study, it was found that WSN strain was the most suscep-
tible to Stachyflin, and then Ibaraki, an avian H5N2 virus
isolated from chicken. Then, antiviral activities of the
compound were evaluated against these viruses in a
mouse model. It was previously revealed that the activity
of Stachyflin was limited as about 40% of viruses were
recovered from lungs of mice injected intraperito-
neally with 2 mg/mouse/day (about 100 mg/kg/day) of
Stachyflin compared to non-injected mice after the
challenge of A/Kumamoto/5/1967 (H2N2) and 400mg/
kg/day of Stachyflin by intraperitoneal injection was not
toxic to mice [15,16]. Stachyflin showed antiviral activity
to reduce 102.0–3.0 virus titer in lungs of mice against H1
and H5 viruses at a dose of 100 mg/kg/day. NA inhibitors,
which are used clinically, showed efficient antiviral activity
in mice at a dose of 20 mg/kg/day [21] whereas Stachyflin
showed the same effect at a dose of 100 mg/kg/day,
which is considered an overdose; therefore, in addition
to the poor pharmacokinetic of Stachyflin [15,16] and
limited spectrum, it may be difficult to apply Stachyflin
in clinical use in the present form. However, Stachyflin
may be clinically used in combination with some NA in-
hibitor such as Oseltamivir.
Antiviral activity of Stachyflin was related with the
structure of the HA. The structure of H1, H2, and H5
HAs, which are susceptible to Stachyflin, closely resem-
ble each other [22] and these HAs including H6 were
identified as group 1 (H1, H2, H5, H6, H8, H9, H11,
H12, H13, and H16) by phylogenetic groupings of HA.
The viruses used in this study have a similar sequence
and structure of the binding pocket for the compound
on the HA; for example, the structure of the binding
pocket of the H1 HA is similar to that of the H5 HA
compared to that of the H3 HA (Figure 4A, B). There
are 6 different amino acids between the H1 and H5 HA
around this region (Figure 4A). In particular, inside the
binding pocket, only one amino acid at position 43 in
the HA2 is different: WSN: asparagine, Ibaraki: lysine,
which is assumed to cause the difference in the suscepti-
bility to Stachyflin due to the difference in the size and
charge of their side chains. For example, lysine has a lar-
ger side chain than asparagine and may make it more
difficult for Stachyflin to enter into the binding pocket;
therefore, the susceptibility to Stachyflin of Ibaraki was
lower than that of WSN (Table 1). On the other hand,
the HAs of the virus strains insusceptible to Stachyflin
have different amino acid sequences in the binding
pocket from that of the susceptible ones. For instance,
14 amino acids were different between the H1 and H3
HAs in the vicinity of the binding pocket, which cause a
structural difference between these HAs (Figure 4B).
In the previous reports, 2 docking models of the HA
and Stachyflin were suggested [14,18]. In one of the


























Figure 4 Structural difference between the H1 and H5 or H3 HA in the binding pocket. The amino acid residues indicated on the HAs
differ between the H1 (PR8) and H5 (A/Vietnam/1194/2004 (H5N1)) or H3 (A/Aichi/2/1968 (H3N2)) (PDB code: 3HMG) HAs around the region of
the binding pocket for Stachyflin. For example, (N/D)-46 indicates that residue 46 in the HA2 is asparagine in H1, but aspartic acid in H5 (A) or H3
(B). (A) The structure and side chains of the H1 HA are in red, and those of the H5 HA are in green. The 2 structures were overlapped and
compared. (B) The structure and side chains of the H3 HA are in blue. [(V/M)-115] indicates that residue 115 in the HA2, which is valine in H1, but
methionine in H3, is not visible.
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bonds with K51 and K121 in the HA2 directly. The
structure of the H3 HA, which is not susceptible to
Stachyflin, was used to make the docking model; there-
fore, the model differed from our model, which uses the
HA of susceptible viruses to Stachyflin. The other docking
model was similar to one of those proposed in the present
study, which is indicated as orange-colored Stachyflin
(Figure 3B). However, since the software program for
docking simulation was different from that used in the
present study, several differences were found between
these models. Indeed, the model which differed from both
the previous docking models was also shown in the
present study. In this study, we were unable to judge
which of these models is more feasible. To further clarify
these discrepancies, it is necessary to perform an X-ray
crystallographic analysis of Stachyflin complex with the
HAs to define the binding site for Stachyflin.
In most studies of HA inhibitors, mutations found in
the HAs of inhibitor-resistant virus are explained as the
cause to reduce their binding affinity with the com-
pound and stabilization of the HA [10,19]. In the present
study, it was indicated that D37, K51, D85, I91, L98, and
T107 were involved in binding affinity with Stachyflin of
the HA by the selection of Stachyflin-resistant virus
clones. On the basis of the computer modeling in this
study, K51 and T107 are postulated to make a hydrogen
bond, which may stabilize the structure of the binding
pocket for Stachyflin; therefore, mutations of these
amino acids should lead to loss of this hydrogen bond,
which may destabilize and distort the binding pocket
and decrease the binding affinity of the HA to Stachyflin.
Indeed, we selected Stachyflin-resistant virus clones
which have the amino acid substitutions, K51R and
T107I. In addition, we also identified amino acid substi-
tutions, D37N and K121E, which are located close to
each other on the HA. Interestingly, some of the crystal
structure of the HA shows the possibility that D37 and
K121 make a hydrogen bond via a water molecule. Then,
similar to K51 and T107, the binding between D37 and
K121 stabilizes the structure of the binding pocket and
mutations of these amino acids lead to distortion of the
binding pocket,decreasing the binding affinity of the HA
to Stachyflin. Indeed, it was indicated by shift of fusion
pH of the mutants that the amino acid substitutions,
D37N, K51R, and T107I, may change the stability of the
HA [22] (Table 2). The other possibility is that D37 and
K121 are predicted to bind directly to Stachyflin based
on the computer docking model (Figure 3B).
Although mutations of D85H, I91F and L98V were re-
sponsible for Stachyflin resistance, their locations on the
HA were far from the region of the binding pocket for
Stachyflin, leading us to investigate the effect of these
mutations. Three-dimensional structure analysis showed
that D85 and K83 of another HA2 subunit made a salt
bridge, which stabilizes the structure of the HA strongly
(Figure 3C) [22]. Amino acid substitution of D85H may
abolish the interaction of the salt bridge and cause struc-
tural changes and destabilization of the HA, including the
binding pocket. In addition, the substitution of aspartic
acid to histidine causes structural and pH-dependent in-
stability of the HA because of its electrostatic force [23].
Histidine collects protons around its side chain under low
pH conditions, which might cause electrostatic repulsion
between the 2 subunits [23]. Additionally, the Stachyflin-
resistant virus clone with an amino acid substitution of
D85H showed a weak hemolysis of cRBC, which may indi-
cate its structural destabilization; therefore, it is assumed
that the structural change of the HA occur by D85H, then
Stachyflin is unable to bind to the HA of the D85H
mutant.
The mutations of I91F and L98V are distant from the
predicted binding pocket for Stachyflin whereas the resi-
due of L98 is reported to be involved in the formation of
the binding pocket for TBHQ, which is located upper
that for Stachyflin, and have a hydrophobic interaction
with TBHQ [19]; however, our docking simulation
showed that Stachyflin was not likely to enter into the
cavity for TBHQ (data not shown), suggesting that L98
may not interact directly with Stachyflin. Likewise, I91
may not interact with Stachyflin directly since there is
no cavity around I91; therefore, amino acid substitutions
of L98V and I91F are postulated to conformational
change the structure of the HA, leading to a change in
the structure or stability of the binding pocket for
Stachyflin.
The frequencies of the Stachyflin-resistant virus clones
selected from WSN and PR8 were 10-3.0-10-4.0. RNA
viruses lack the ability to detect and repair mistakes
during replication and, as a result, the mutation rate can
be as high as 1 mutation per each 103-105 bases copied
per replication cycle [24]. Based on these data, selection
of these resistant variants was not ‘rapid’ but same as
other drugs. Resistant variants from Ibaraki and Taiwan
were selected in the presence of Stachyflin by 3 passage,
indicating that the frequency of the virus clones were
much lower than those of WSN and PR8. Structural
analysis of the HA indicated that the lower stability of
the HA by amino acid substitution for the Stachyflin-
resistant virus lead to inefficient virus replication. These
results indicate that the resistant virus clones exist in
virus population and were isolated only under limited
conditions.
Conclusion
In the present study, we found antiviral activity of
Stachyflin against A(H1N1)pdm09, H5, including highly
pathogenic avian influenza viruses, and H6 viruses, and
identified a potential binding pocket for Stachyflin, which
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differs from that previously proposed [12,14]. We hereby
propose that molecular structures in the potential binding
site for Stachyflin depend on the HA of different subtypes,
affecting the susceptibility to this compound. Additionally,
the present results suggest that further precise analysis of
fusion inhibitors reveals their unidentified activities and
more suitable docking poses with the HA, contributing to




Stachyflin obtained from Stachybotrys sp. has already been
purified and characterized at Discovery Research Labora-
tories, Shionogi & Co., Ltd [25]. Stachyflin powder was
dissolved in dimethyl sulfoxide (DMSO) (Nacalai Tesque,
Kyoto, Japan) and was further diluted in each test medium.
Cells and viruses
MDCK cells [26] were grown in Minimum Essential
Medium (MEM) (Nissui Pharmaceutical, Tokyo, Japan)
supplemented with 0.3 mg/ml L-glutamine, 5% fetal
bovine serum (SAFC Biosciences, Street Lenexa, KS,
U.S.A.), 100 U/ml penicillin G, 0.1 mg/ml streptomycin,
and 8 μg/ml gentamicin. Human embryonic kidney
(293T) cells were maintained in Dulbecco's Modified
Eagle's Medium (DMEM) (Life Technologies Japan,
Tokyo, Japan) supplemented with 0.3 mg/ml L-glutamine,
10% FBS (Cambrex, Grand Island, NY, U.S.A.), and
antibiotics. Both cell lines were maintained at 37°C in a
5% CO2 atmosphere. The influenza virus strains used in
the present study are listed in Table 1. All viruses were
propagated in the allantoic cavities of 10-day-old embry-
onated chicken eggs at 35°C for 30–48 h. Before the
infectious allantoic fluids were harvested, the eggs were
chilled at 4°C overnight, and the harvested allantoic
fluids were stored at −80°C.
In vitro antiviral assay
Anti-influenza virus activity of Stachyflin was evaluated
by its inhibition of virus-induced CPE in MDCK cells.
The virus was inoculated onto confluent monolayers of
MDCK cells at the titer of 100 TCID50/ml and virus was
adsorbed to the cells at 4°C for 1 h. Unbound viruses
were removed by washing the cells with PBS. MEM
containing 1.0% DMSO and various concentrations of
Stachyflin, from 0.004 to 6.50 μM, were added to the
cells and incubated at 35°C. After 72 h, antiviral activity
was evaluated by virus-induced CPE and expressed as
50% effective concentration of the compound (EC50).
In vivo antiviral assay
Under anesthesia, 30 μl of WSN or Ibaraki containing
10 50% mouse infectious dose (MID50) was intranasally
inoculated into 4-week-old female BALB/c mice (Japan
SLC, Shizuoka, Japan). For the anesthesia, a mixture of
tiletamine hydrochloride (20 mg/kg) (United States
Pharmacopeia, Rockville, MD, U.S.A.), zolazepam hydro-
chloride (20 mg/kg) (United States Pharmacopeia), and
xylazine (20 mg/kg) (Bayer HealthCare, Leverkusen,
Germany) was injected intraperitoneally into mice. After
the virus inoculation, 100 μl of the solutions containing
various concentrations of Stachyflin in polyethylene
glycol 400 (Nacalai Tesque) were intraperitoneally ad-
ministered to each group every 12 h for 72 h. Control
mice were injected with only polyethylene glycol 400
after the challenge. At 72 h post-inoculation, mice were
euthanized and the lungs were collected for virus recov-
ery. The supernatants of 10% lung homogenates were
inoculated onto confluent monolayers of MDCK cells
and the virus titers were calculated using the method of
Reed and Muench and expressed as TCID50/g of tissue
samples [27]. All animal experiments were carried out in
self-contained isolator units (Tokiwa Kagaku, Tokyo,
Japan) at the BSL-2 or BSL-3 facility of the Graduate
School of Veterinary Medicine, Hokkaido University,
Japan. The institutional animal care and use committee
of the Graduate School of Veterinary Medicine autho-
rized this animal experiment (approval numbers: 10–
1052) and all experiments were performed according to
the guidelines of this committee.
Selection and characterization of stachyflin-resistant virus
clones
WSN, Ibaraki, PR8, and Taiwan were diluted 10-fold series
and inoculated on MDCK cells in the presence of various
concentrations (0.26, 0.52, 1.30, and 6.50 μM) of Stachyflin.
After 72 hours incubation at 35°C, the supernatant of the
highest dilution series in the wells in which CPE was ob-
served was collected. EC50 of the viruses were determined
as described above and their susceptibilities to the com-
pound were evaluated compared with the parent virus. If
the recovered virus did not show increase of EC50, the
virus was passaged by same method. For cloning of the vi-
ruses, each passaged virus was inoculated on MDCK cells
and the cells were then overlaid with MEM containing 1%
bacto-agar (Becton, Dickinson, and Company, Franklin
Lakes, NJ, U.S.A.) in the presence of 6.50 μM Stachyflin.
After 48 h of incubation at 35°C, the cells were stained
with 0.014% neutral red (Kanto Chemical, Tokyo, Japan)
and the plaques were collected. Individual clones were in-
cubated on MDCK cells in the presence of 6.50 μM
Stachyflin at 35°C. After 72 h incubation, each supernatant
was collected and stored at −80°C.
Sequence analysis of virus genes
Viral RNA was extracted from the allantoic fluid of em-
bryonated chicken eggs or the supernatant of MDCK
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cells by TRIzol LS Reagent (Invitrogen, Carlsbad, CA,
U.S.A.) and reverse-transcribed with the Uni12 primer [28]
and M-MLV Reverse Transcriptase (Invitrogen). The
full-length cDNA of the 8 gene segments was amplified
by polymerase chain reaction (PCR) with gene-specific
primer sets reported previously [29] or designed in the
present study. The sequences of primers designed in the
present study are as follows: PB2-826F: GTTAGGAG
AGCAACAGTATCAG, PB2-922R: CAGCTTGCTCTT
CTGTTGG, PB1-1240F: GGAATGATGATGGGCAT
GTT, PB1-1472R: CATCAGACGATTGGAGACCG, PA-
723F: CATTGAGGGCAAGCTTTCTC, PA-1110R: CAT
GTTCTCACCTAATGCCC. Direct sequencing of all 8
gene segments was performed using an auto sequencer,
3500 Genetic Analyzer (Applied Biosystems, Foster City,
CA, U.S.A.). To identify amino acid substitutions which
should contribute to the susceptibility of viruses, the
nucleotide sequences of Stachyflin-resistant virus clones
were proofread, and the deduced amino acid sequences
were compared with the wild-type virus using GENETYX-
WIN version 10 (Genetyx, Tokyo, Japan).
Reverse genetics
WSN and their mutants were generated by reverse gen-
etics (rg) according to the procedure reports [30,31],
which were named rgWSN, rgR1, rgR2, rgR3, and rgR4,
respectively (Table 3). Briefly, viral RNA was extracted
and amplified by RT-PCR. The PCR product of each
gene segment was cloned into pHW2000 plasmid [31].
Eight genome sets of plasmid were transfected to MDCK
and 293T cells and incubated at 37°C for 30 h and then
35°C. After 48 h, rgWSN was collected. All of the col-
lected viruses were propagated in MDCK cells at 35°C
and collected after 48 h.
Site-directed mutagenesis
Stachyflin-resistant virus clones with the amino acid sub-
stitutions were generated by site-directed mutagenesis as
described previously [31]. Briefly, the residue of amino
acid substitutions in the HA2 were introduced into the
HA genes of WSN using a Quik-Change II site-directed
mutagenesis kit (Agilent, Santa Clara, CA, U.S.A.) accor-
ding to the manufacturer’s instructions. The mutant vi-
ruses, rgR1, rgR2, rgR3, and rgR4, were rescued by reverse
genetics as described above, and the entire genomes of the
8 gene segments were sequenced to confirm the existence
of the introduced mutations and the absence of undesired
mutations.
Hemolysis assay
Hemolysis assay was performed as described previously
[32]. Briefly, WSN and Stachyflin-resistant virus clones
were centrifuged at 25,000 rpm for 1.5 h and the pellets
were resuspended in PBS (pH 7.2). Virus concentrates
were added to 1 ml of 1% cRBC in saline buffered with
0.1 M citric acid-sodium citrate at a final concentration
of 200 HA unit and incubated on ice for 1 h. After the
incubation at 37°C for 1 h with mixing every 10 min, the
cells were sedimented by centrifugation and the super-
natants were measured for hemoglobin at 540 nm.
Protein and ligand structures
Three dimensional models of the H1 HA (WSN) and H5
HA (Ibaraki) molecules were constructed based on the
HA crystal structures of PR8 and A/Vietnam/1194/2004
(H5N1), respectively (PDB codes: 1RU7 and 2IBX). After
100 models of the HA trimer were generated using MOD-
ELLER 9v6 [33], a model was chosen by a combination of
the MODELLER objective function value and the discrete
optimized protein energy (DOPE) statistical potential score
[34]. The HA model was evaluated using PROCHECK [35]
and VERIFY3D [36]. The structure of Stachyflin (CID:
493326) was downloaded from the PubChem database.
Molecular docking
Molecular docking simulations of the HA and Stachyflin
were performed using the Molegro Virtual Docker (MVD)
with the default parameter settings [37].
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